 TORONTO, ON ACCESSWIRE December 3, 2019 Edesa Biotech, Inc. NASDAQ:EDSA, a clinical-stage biopharmaceutical company, today reported that the companys lead product candidate, EB01, has demonstrated positive safety data in healthy volunteers participating in its ongoing Phase 2b clinical study in chronic allergic contact dermatitis ACD, a debilitating disease that is frequently caused by allergens present in the workplace. The healthy volunteer cohort at the outset of Edesas study is designed to clear the way for using the experimental topical treatment on the face of ACD patients. Due to the high prevalence of symptoms on the face of ACD patients, the expansion of the study to facial symptoms is expected to address a key aspect of the disease, while broadening the potential patient population. 